March 17, 2023
1 min learn
Supply/Disclosures
Printed by:
Barrera TM, et al. The prevalence of dupilumab-associated antagonistic occasions amongst Black/African American grownup sufferers with atopic dermatitis: A retrospective chart overview. Offered at: Pores and skin of Shade Society Scientific Symposium; March 16, 2023; New Orleans.
Disclosures:
Barrera stories no related monetary disclosures.
Key takeaways:
- Fewer Black vs. white sufferers handled with dupilumab for atopic dermatitis skilled antagonistic occasions (25% vs. 51%).
- The distinction in antagonistic occasions was not statistically significance.
NEW ORLEANS — Though Black sufferers with atopic dermatitis handled with dupilumab skilled fewer antagonistic occasions than their white counterparts, the distinction didn’t attain statistical significance, in keeping with a poster offered right here.
“We needed to have a look at what the antagonistic occasions have been, but additionally, what’s the breakdown whenever you take a look at it by race,” Tatiana M. Barrera, BA, a fourth-year medical pupil on the College of California, Riverside College of Medication and the lead creator of the examine, instructed Healio. “We all know that in scientific trials, the illustration of our pores and skin of coloration sufferers akin to Black, Latino and Asian are fairly low, so we needed to have a look at real-world knowledge to see if the antagonistic occasions are much like these in scientific trials.”
The investigators carried out a retrospective chart overview of sufferers handled with subcutaneous dupilumab 300 mg/2 mL each 2 weeks. Prescriptions have been crammed between 2017 and 2021.
Of 445 people included within the overview, 49.21% have been white, 29.21% have been Black or African American, 17.3% have been one other pores and skin of coloration demographic and 4.27% have been unknown or declined to reply.
There have been 25 dupilumab-associated antagonistic occasions that occurred within the 130 Black sufferers, 51 that occurred within the 219 white sufferers, 12 that occurred within the 77 different pores and skin of coloration sufferers and 5 that occurred within the 19 unknown/declined to reply sufferers.
Whereas numerically decrease antagonistic occasions have been reported within the pores and skin of coloration populations, the numbers didn’t attain statistical significance.
“The most important take house is that dupilumab is a medicine that’s protected for individuals who come from completely different backgrounds,” Barrera instructed Healio. “As clinicians we will have these discussions with our sufferers, deal with it with cultural sensitivity, [discuss] if there are some hesitations with injections or biologic drugs. Once you actually go over these real-life knowledge … this remedy is fairly protected.”
